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Abstract
Responses of human neutrophils to TNF-a are complex and multifactorial.
Exposure of human neutrophils to TNF-a in vitro primes the respiratory burst,
delays apoptosis and induces the expression of several genes including chemokines,
and TNF-a itself. This study aimed to determine the impact of TNF-a exposure on
the expression of neutrophil genes and proteins that regulate apoptosis.
Quantitative PCR and RNA-Seq, identified changes in expression of several
apoptosis regulating genes in response to TNF-a exposure. Up-regulated genes
included TNF-a itself, and several anti-apoptotic genes, including BCL2A1,
CFLAR (cFLIP) and TNFAIP3, whose mRNA levels increased above control values
by between 4-20 fold (n¼ 3, P< 0.05). In contrast, the expression of pro-apoptotic
genes, including CASP8, FADD and TNFRSF1A and TNFRSF1B, were significantly
down-regulated following TNF-a treatment. These changes in mRNA levels were
paralleled by decreases in protein levels of caspases 8 and 10, TRADD, FADD,
TNFRSF1A and TNFRSF1B, and increased cFLIP protein levels, as detected by
western blotting. These data indicate that when neutrophils are triggered by TNF-a
exposure, they undergo molecular changes in transcriptional expression to up-
regulate expression of specific anti-apoptotic proteins and concomitantly decrease
expression of specific proteins involved in death receptor signaling which will alter
their function in TNF-a rich environments.
Introduction
TNF-a is a pleiotropic cytokine that regulates the activity of
many immune cells and tissues. It plays an important role in
a number of physiological processes, such as cellular
differentiation, but is also implicated in many pathological
processes [1–3]. Apart from its role in regulating acute and
chronic inflammation, it is also involved in inflammatory
diseases, such as septic shock, Crohn’s Disease, systemic
lupus erythematosus and rheumatoid arthritis [4–8].The
central role of TNF-a in many of these conditions is
highlighted by the improvement in disease that often follows
anti- TNF-a therapy, notably in rheumatoid arthritis and
juvenile idiopathic arthritis where timely anti-TNF-a
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therapy can lead to dramatic improvements in disease in
many patients [9–11]. Myeloid cells, including neutrophils,
monocytes, macrophages and dendritic cells are recognized
producers of TNF-a. This cytokine can mediate its effects on
cells by acting alone, or in combination with other cytokines,
such as RANKL (Receptor Activator of Nuclear factor
Kappa-B Ligand) [12, 13].
The effects of TNF-a on target cells are varied, and
activation is mediated by the surface receptors, TNFR1
(TNFRSF1A, p55/p60) and TNFR2 (TNFRSF1B, p75/p80).
Ligation of these receptors can lead to activation of a range of
cellular responses, including cell survival, apoptosis, differ-
entiation and proliferation [14, 15].The overall response of
cells to TNF-a is dependent upon the cell type, the
concentration of TNF-a, receptor binding and the intracel-
lular signaling pathways that are activated. For example,
TNF-a signaling can lead to the generation of an apoptotic
signal via FADD-mediated activation of caspase 8, whereas
TRADD/TRAF-2 (TNF receptor associated factor-2) activa-
tion can lead to activation of NF-kB and triggering
of downstream events that result in increased gene
expression leading to an anti-apoptotic or a proliferative
response [16–20].
Neutrophils play a central role in TNF-a signaling in
immune activation during inflammation, by both generating
TNF-a and responding to it to become activated [21–27].
Human neutrophils can be stimulated to express and release
TNF-a, and this cytokine is expressed on the cell surface of
blood neutrophils of patients with uncontrolled rheumatoid
arthritis [28]. Moreover, the expression of surface TNF-a on
blood neutrophils decreases in line with disease improve-
ment in patients who respond to anti-TNF-a therapy [28].
Neutrophil responses to TNF-a are complex and varied in
that low concentrations (10 ng/mL) can ‘‘prime’’ the
respiratory burst, up-regulate surface receptors, stimulate
adhesion and delay apoptosis, whereas higher concentra-
tions (>30 ng/mL) can promote apoptosis [27, 29]. In view
of these varied neutrophil responses triggered by TNF-a
stimulation, it is important to define responses to this
molecule under conditions that mimic acute and chronic
inflammation. On the one hand, neutrophils can express
TNF-a on their cell surface and release this molecule into the
extracellular environment, thereby triggering events in
adjacent cells. Alternatively, they themselves are stimulated
by TNF-a, into either anti- or pro-apoptotic pathways,
depending on the local concentration of this cytokine.
The aim of this study was to determine the molecular
events that regulate neutrophil responses to TNF-a
signaling. We demonstrate that in response to low
concentrations of TNF-a, neutrophils are activated to
express TNF-a itself, exhibit delayed apoptosis and in
parallel, down-regulate expression of a number of genes and
proteins that mediate death-receptor signaling. These
processes could therefore contribute to the fine tuning of
responses of human neutrophils to TNF-a in inflammatory
conditions.
Materials and Methods
Reagents
The following reagents were used in this study: Polymorph-
prep (Axis-Shield); RPMI 1640 media (Gibco, Paisley);
Rapid Romanowsky stain (HD Supplies, Aylesbury, Bucks,
UK); human AB serum and propidium iodide (Sigma,
Gillingham, Dorset); TRIZOL, Superscript III First Strand
cDNA Synthesis kit and FITC-Annexin V (Invitrogen);
RNAeasy kit, DNase and SYBR Green PCR kit (Qiagen);
polyvinylidenedifluoride (PVDF) membranes and Immobi-
lon Western Chemiluminescent HRP Substrate (Millipore).
Primary antibodies (1:1,000) were from Cell Signaling while
anti-actin was fromAbcam. Secondary antibodies (1:10,000)
were anti-mouse IgG (Sigma) and anti-rabbit IgG (GE
Healthcare).
Isolation of neutrophils
This study was approved by the University of Liverpool
Committee for Research Ethics. Neutrophils were isolated
from heparinised peripheral blood of healthy donors using
Polymorphprep, according to the manufacturers instruc-
tions. Red blood cell contamination was removed by
hypotonic lysis. Neutrophils were re-suspended in RPMI
1640 media to a concentration of 106/mL. Neutrophil
purity was assessed by staining with Rapid Romanowsky
stain and was >97%. Re-suspended neutrophils were
incubated up to 6 h or overnight, with RPMI 1640 media at
378C in a 5% CO2 incubator, with or without 10% (v/v)
human AB serum, with and without TNF-a, as indicated
in the text.
RNA isolation and real-time PCR analysis
After incubation in the absence or presence of TNF-a (10 ng/
mL), neutrophils were pelleted, and RNA from the pellet was
extracted with Trizol reagent using an RNAeasy kit, which
included a DNA digestion step. Total RNA concentration
and integrity was assessed using the Agilent 2100 Bioanalyser
RNA Nano chip. cDNA was synthesized from 200 ng of total
RNA from each sample, using the Superscript III First Strand
cDNA Synthesis kit, in a 20mL reaction volume, as per the
manufacturer’s instructions. Quantitative PCR analysis was
carried out with the SYBR Green PCR kit, as per the
manufacturer’s instructions, using a Roche 480 LightCycler
in a 96-well plate using 1mL of the above cDNA suspension
in a 20mL reaction volume. Target gene expression was
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quantified against a panel of housekeeping genes (GAPDH,
b-2 microglobulin, b-actin, peptidylprolyl isomerase A).
Initially, a Human Apoptosis RT2 Profiler PCR Array (SA
Biosciences) was used to detect neutrophil transcripts whose
levels were regulated by TNF-a treatment. Thereafter,
specific primers for genes of interest were purchased from
PrimerDesign and Eurofins (Table 1). Levels of gene
expression were normalized to the housekeeping genes by
comparing Ct values, and data presented are normalized to
GAPDH [30].
RNA-sequencing: Library generation and
sequencing
Total RNA was enriched for mRNA using poly-A selection,
and standard Illumina protocols were used to generate 50bp
single-end read libraries, which were analyzed on a HiSeq
2000 instrument. Reads were mapped to the human genome
(hg19) using TopHat v1.4.1 [31, 32], and annotated using
Cufflinks v1.3.0 [32].Statistical analysis was carried out
using Cuffdiff [33]. The RNA-Seq data discussed in this
manuscript have been deposited in the NCBI’s Gene
Expression Omnibus (GEO) and are accessible through
GEO Series accession number GSE40548 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE40548).
Bioinformatics
Bioinformatics analysis was carried out using Ingenuity
Pathway Analysis (Ingenuity1 Systems, www.ingenuity.com).
Western blotting
Isolated neutrophils were pelleted and washed with
Phosphate Buffered Saline and lysed with boiling Laemmli
lysis buffer at a concentration of 106 cells/10mL. Protein
lysates for each sample were loaded onto a 10 % resolving
polyacrylamide gels (SDS-PAGE), and gel electrophoresis
was run for 1 h. Separated proteins were transferred to
polyvinylidenedifluoride (PVDF) membranes by electro-
phoresis for 80min. The membranes were blocked with 5%
non-fat skimmed milk for 1h, incubated with primary
antibodies and then incubated overnight with gentle
agitation at 48C. Primary antibodies were: rabbit anti-
human TNFR1 (TNFRSF1A), TNFR2 (TNFRSF1B),
TRADD, FADD, Caspase-10, FLIP (CFLAR) or mouse
anti-human Caspase-8. After incubation with appropriate
secondary antibodies, detection was by Immobilon
Western Chemiluminescent HRP Substrate and careful
exposure to film to avoid signal saturation. The mem-
branes were then stripped for 30min using stripping buffer
(50mM glycine, 150 nM NaCl, 0.1% (v/v) Tween-20, HCl
to pH 2.5), then re-blocked and incubated with a
monoclonal mouse anti-actin antibody followed by anti-
mouse IgG secondary antibody. Band intensity was
measured as an integrated density value, as determined
by AQM Advance 6 software.
Neutrophil apoptosis by flow cytometry
After incubation in the absence or presence of TNF-a
(10 ng/mL), neutrophils (2.5 104) were stained with
Annexin V-FITC for 15min (to measure early apoptosis)
and then incubated with propidium iodide (1mg/mL) (to
detect changes in membrane permeability in late apoptotic
cells). Stained cells were then analyzed on a Guava
EasyCyte flow cytometer. Five thousand events were
analyzed per sample.
Table 1. PCR primer sequences.
Gene
symbol
Product
length Sequence (50-30)
TNF 219 f-CAGAGGGCCTGTACCTCATC
r-GGAAGACCCCTCCCAGATAG
BCL2A1 82 f-GAATAACACAGGAGAATGGATAAGG
r-CCAGCCAGATTTAGGTTCAAAC
CFLAR 93 f-ATAGATGTGGTTCCACCTAATGTC
r-GTAGAGCAGTTCAGCCAAGTC
TNFAIP3 113 f-AACATTTTGCTGCTGCCTCA
r-TCCTTCAAACATGGTGCTTCC
APAF1 94 f-CTTCCAGCCAACCTATTTTCCT
r-CCTGATTAACCTTGGAGATAAAAGAA
BAX 101 f-ATGGAGCTGCAGAGGATGAT
r-CAGTTGAAGTTGCCGTCAGA
CASP10 124 f-GGAACGGACACACAACTCTC
r-AGCCCACTCACTTACAGACTAA
CASP8 95 f-AGTAAGCAACAAGGATGACAAGA
r-ATCAATCAGAAGGGAAGACAAGTT
FADD 176 f-CACAGACCACCTGCTTCTGA
r-CTGGACACGGTTCCAACTTT
FAS 104 f-TGTAGTATGAATGTAATCAGTGTATGT
r-GATATTTCAGCAAAAGGTCATAGC
TNFRSF1A 88 f-TGTGTCTCCTGTAGTAACTGTAAG
r-AGTCCTCAGTGCCCTTAACA
TNFRSF1B 145 f-GTCCACACGATCCCAACAC
r-CACACCCACAATCAGTCCAA
TRADD 88 f-GGTGCATCATTGGGGATTCT
r-GGGAGAAGGTGAGGCTGAT
GAPDH 106 f-CTCAACGACCACTTTGTCAAGCTCA
r-GGTCTTACTCCTTGGAGGCCATGTG
ACTB 211 f-CATCGAGCACGGCATCGTCA
r-TAGCACAGCCTGGACAGCAAC
B2M 114 f-ACTGAATTCACCCCCACTGA
r-CCTCCATGATGCTGCTTACA
PPIA 60 f-GCTTTGGGTCCAGGAATGG
r-GTTGTCCACAGTCAGCCATGGT
Chiewchengchol et al. Differential changes in gene expression in human neutrophils
© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 3
Statistical analyses
Statistical analyses were performed by using Student’s t-test.
Data are shown as the mean SD, and the statistical
significance of the differences between groups was deter-
mined. Differences with a P-value of <0.05 were considered
statistically significant.
Results
Effect of TNF-a on neutrophil apoptosis and gene
expression
Incubation of human neutrophils with 10 ng/mL of TNF-
a resulted in delayed apoptosis, as determined by
decreased annexin V binding (due to surface phospha-
tidylserine exposure). Previous work has shown that this
cell death is caspase dependent [34, 35]. After 18 h
incubation in the absence of TNF-a, levels of apoptosis
were 65% ( 4 %) while in TNF-a-treated cells, the level
of apoptosis was significantly lower (53% 6%, n¼ 3,
P< 0.05), confirming previous observations (Supplemen-
tary Figure S1) [36].
It has been previously reported that this concentration of
TNF-a also induces gene expression [23, 27] and so we
initially used a commercial PCR array to identify genes
involved in the regulation of apoptosis that were affected by
this TNF-a treatment. The PCR array that we used (see
Materials and Methods) measured the relative expression of
84 key genes in the regulation of apoptosis (see http://www.
sabiosciences.com/rt_pcr_product/HTML/PAHS-012Z.
html for a full list of genes). Of these 84 genes, 13 were
selected for further analysis (see list in Table 1) based either
on their relative transcript abundance in neutrophils (Ct
values of 20 or less) or on the basis that their relative levels
were affected, positively or negatively, by TNF-a treatment.
Repeat experiments, on neutrophils isolated from different
donors, as indicated in the figure legends, were then
performed in individual quantitative PCR experiments
using primers described in Table 1.
Changes in expression of genes involved in death
receptor signaling
Figure 1 shows fold change in mRNA levels quantified by
real-time PCR (normalized to GAPDH) following the
addition of TNF-a (10 ng/mL) to neutrophils for 1 h. One
of the genes whose expression was up-regulated was TNF-a
itself, expression of which increased by over 20-fold (Fig. 1).
In addition, mRNA levels for TNFAIP3 (A20) increased by a
similar magnitude following TNF-a treatment. Transcripts
for BCL2A1, CFLAR (FLIP), and FAS were also up-
regulated. However, expression of some genes involved in
apoptosis control was significantly down-regulated follow-
ing TNF-a treatment. These down-regulated genes included
APAF1, CASP8, CASP10, FADD, TNFRSF1A and
TNFRSF1B.
Figure 1. TNF-a stimulation of neutrophil gene expression. Neutrophils were incubated for 1h in the absence (control) or presence of TNF-a (10 ng/mL).
Fold change in mRNA levels were quantiﬁed by real-time PCR (normalized to GAPDH) (black bar) and RNA-Seq (grey bar) (mean fold change SD, n¼ 3
for each dataset). Abbreviations: BCL2A1 (BFL-1)¼ B-cell lymphoma 2-related protein A1; CFLAR (FLIP)¼CASP8 and FAS-like apoptosis regulator of
FLICE-like inhibitory protein; TNFAIP3¼ Tumor necrosis factora-induced protein 3; Apaf-1, Apoptotic protease activating factor 1; BAX, Bcl-2-associated
X protein; CASP10, Caspase 10; CASP8, Caspase 8; FADD, Fas-Associated protein with Death Domain; TNFRSF1A&1B (TNFR1&2), Tumor necrosis factor
receptor superfamily member 1A&1B or Tumor necrosis factor receptor 1&2; TRADD, Tumor necrosis factor receptor type 1-associated DEATH domain
protein. For all data obtained by qPCR, the differences in expression levels following TNF-a treatment were signiﬁcantly different to control values
(P< 0.05).
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In a parallel study, we used RNA-Seq to measure the
transcriptome of human neutrophils and identify changes
induced by similar TNF-a treatment [36]. The qPCR results
were therefore compared with results of these RNA-Seq
experiments, and both the qualitative and quantitative
profiles of altered gene expression observed following TNF-
a treatment using these two independentmethods, were very
similar (Fig. 1).
Bioinformatics analyses of the changes in gene expres-
sion following stimulation with TNF-a for 1 h are shown
in Figure 2. This scheme was generated by Ingenuity
Pathway Analysis (IPA) software (Ingenuity
1
Systems,
http://www.ingenuity.com/) in which the fold change in
gene expression values between the control (untreated)
samples and the TNF-a treated samples were projected
onto the Death Receptor Signaling pathway. In this
scheme, mRNA levels that decreased following TNF-a
treatment are shown in green, while those whose levels
increased are shown in red. This scheme predicts that
signaling of apoptosis via a range of death receptors would
be down-regulated as a result of the TNF-a treatment of
neutrophils.
Time course of TNF-a induced mRNA changes
The above transcriptome analyses were performed after 1 h
incubation in the presence and absence of TNF-a used at
10 ng/mL. In order to determine the kinetics of mRNA
expression in response to TNF-a stimulation, neutrophils
were incubated for up to 6 hwith TNF-a and changes in gene
expression were determined by qPCR. Maximal changes in
gene expression were detected by 1 h incubation with TNF-
a, and extension of the incubation time to either 3 or 6 h did
not result in any changes in expression of those genes of
interest, above those observed after 1 h incubation (Fig. 3).
Changes in protein levels following TNF-a
treatment
We then determined if these TNF-a-induced changes in
mRNA levels were accompanied by corresponding changes
in protein levels. Neutrophils were incubated for up to 6 h in
the absence and presence of TNF-a (10 ng/mL). No
significant changes in protein levels were detected by
Western blotting of protein lysates prepared following 2 h
Figure 2. Bioinformatics analyses reveal changes in expression of genes associated with the Death Receptor Pathway. Data represent the mean fold
change (n¼ 3) in expression following stimulation with TNF-a for 1 h compared to untreated control measured using qPCR. Up-regulated genes are
shown in red and down-regulated genes are shown in green, the analysis was generated using IPA (Ingenuity). Similar results were obtained when the
RNA-Seq data were analyzed in this way.
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incubation (data not shown), but for most proteins under
investigation maximal changes in expression were detected
by 4–6 h incubation (data not shown). Figure 4 shows
representative Western blot data and a summary of
quantified data for FLIP, FADD and caspase 10 measured
4 h after TNF-a treatment, while data for TNFR1, TNFR2,
TRADD and caspase 8 are shown 6 h after TNF-a treatment.
In line with the qPCR/RNA-Seq data, expression of FLIP
protein was significantly enhanced following TNF-a
treatment (P< 0.05), while the expression of all other
proteins investigated significantly decreased following TNF-
a treatment (P< 0.05). Thus, levels of expression of TNFR1,
TNFR2, TRADD, and FADD were all significantly decreased
after treatment. The antibody that we used in these studies
detects both the pro- (inactive) and the cleaved (activated)
forms of caspase 8 (Fig. 4F), and so we were able to quantify
levels of both forms of this protein. Following TNF-a
treatment, levels of both the inactive pro-form of the enzyme
and the activated, cleaved form were decreased, indicating a
down-regulation of cellular protein levels that were
independent of the level of apoptosis (which was decreased
by TNF-a exposure). The antibody that we used to detect
caspase 10, only detected the uncleaved (inactive), pro-form
of the enzyme, which was decreased after TNF-a treatment
(Fig. 4G). As apoptosis was decreased in the presence of
TNF-a, this decrease in protein was likely to reflect
decreased expression rather than increased cleavage.
Discussion
This data presented in this study describe a potential new
mechanism by which human neutrophils control their
responsiveness to TNF-a via up-regulation of the expression
of anti-apoptotic genes and the simultaneous down-
regulation of expression of genes involved in death-receptor
signaling. Such a mechanism would be predicted to enable
neutrophils to survive and maintain their functions within
TNF-a-rich environments during inflammation. For exam-
ple, in rheumatoid arthritis TNF-a plays a central role in
pathology and neutrophil function is activated in the blood
of untreated patients [28]. In such a disease, the mechanism
described in this report would be predicted to affect the way
in which neutrophils would respond to long term exposure
to pathological levels of this cytokine. Down-regulation of
death receptor signaling would limit the responsiveness of
neutrophils to TNF-a, and hence limit their continued
activation by this pro-inflammatory cytokine. TNF-a
expression itself is markedly up-regulated when neutrophils
are exposed to TNF-a, and so neutrophils can actively
contribute to the TNF-a signaling network that is observed
in a number of inflammatory conditions (e.g. in rheumatoid
arthritis) without the possibility of continuous, autocrine-
activation.
The effects of TNF-a on human neutrophils are complex
and varied, and are reported to be both concentration- and
time-dependent, as well as having differential effects on
different sub-populations of cells [26, 27, 29, 37–43].
Previous reports have shown that TNF-a down-regulates
neutrophil function by induction of shedding of TNFR1 and
TNFR2 [44], or internalization of TNFR1 [45], which may
partly explain de-sensitisation of responsiveness during
continuous exposure to this cytokine. Our data demonstrate
that decreased de novo gene expression is also important in
the modulation of neutrophil responses to TNF-a, by down-
regulation of key proteins that are involved in TNF-a
mediated apoptosis. Such a mechanism may explain
limitation of neutrophil responses to either exogenous or
autocrine TNF-a.
Most studies of neutrophil gene expression have, to date,
focused upon identifying those genes whose expression is
elevated or activated following inflammatory challenge. Few
studies have reported decreased gene expression following
activation, despite the fact that down-regulation of key
proteins can have a profound effect on neutrophil function
and their subsequent contribution to infectious or inflam-
matory challenge. Here, we show significant down-regula-
tion of a number of genes that control responsiveness to
death signals. The mechanisms responsible for decreased
expression of particular genes are not known, but may
involve activation of transcriptional repressors or chromatin
re-modelling, such as increased methylation or de-
Figure 3. Changes TNF-a-activated gene expression are maximal after
1 h stimulation. Neutrophils were incubated for up to 6 h in the absence
or presence of TNF-a (10 ng/mL). Gene expression was analyzed by real-
time PCR (normalized to GAPDH). Samples were collected 1 h (black bar),
3 h (grey bar), and 6 h (open bar) after addition of TNF-a. Values shown
are mean ( SD) of three separate experiments. At 1 h time point, the
changes in mRNA levels of all transcripts measured following TNF-a
treatment were signiﬁcantly different to untreated values (P< 0.05).
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Figure 4. Changes in expression of pro- and anti-apoptotic proteins after TNF-a treatment. Neutrophils were incubatedwith TNF-a (10 ng/mL) and at 2,
4, and 6 h incubation, protein extracts were made and subject toWestern blotting. In each panel, representativeWestern blots of the protein of interest
are shown, togetherwith the corresponding actin control blot to ensure equivalence of protein load. Underneath each blot in each panel is summary data
of three separate experiments showingmean values ( SD). For all data shown, therewas a statistically signiﬁcant difference between control (untreated)
and TNF-a-treated neutrophils (P< 0.05). Panels A, D, and G are analyses after 4 h incubation with TNF-a, while for the remaining panels, samples were
analyzed after 6h incubation. For panel F, representative blots of pro-capsase 8 (inactive) and cleaved (active) caspase 8 are shown, while quantitative
data show the combined levels of pro- and cleaved-caspase 8.
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acetylation of chromatin. While changes in mRNA levels
were maximal 1 h after stimulation with TNF-a, incubation
periods in excess of 4 h were required before corresponding
changes in protein levels were detected. This time delay
between a decrease inmRNA and a decrease in protein levels,
would allow an appropriate time window for the neutrophil
to positively respond to the cytokine and then express new
proteins, in this case anti-apoptotic proteins, that alter cell
function. There was some variability in the time after
incubation with TNF-a before the changes in protein levels
were significantly different: some detectable by 4 h of
incubation, others only detectable after 6 h incubation.
This is possibly a consequence of differences in the turnover
rates of these different proteins.
Using both quantitative PCR and RNA-Seq to measure
transcript levels in neutrophils following TNF-a treatment,
we demonstrated a very close correlation between the sets of
data generated by these two independent methods. The
former method is commonly-used to measure expression
levels of specific transcripts in human neutrophils, but the
latter has not been used extensively to quantify the
transcriptome of these cells. The benefits of RNA-Seq over
other transcriptome methods (qPCR, arrays) are signifi-
cant [31, 32], and together with the ever-decreasing costs of
this technology, make this approach a cost-effective way to
study neutrophil function, both in vitro and ex vivo. One
major difference in the results obtained by these two
methods was in transcript levels for CASP10, which were
decreased following TNF-a treatment when measured by
qPCR, but increased slightly when measured by RNA-Seq.
The reasons for this apparent difference are unknown, but
this observation was consistently found in our PCR
experiments (n¼ 6), that were performed with a different
set of donors as those used for RNA-Seq. Hence, this
difference may represent donor variation.
This study demonstrated that several genes involved in
NF-kB signaling pathway were up-regulated (e.g. NFKB1,
NFKB2 and REL, as shown in Figs., 2 1) when neutrophils
were exposed to TNF-a. However, TNF-a down-regulates
TNFR1 and TNFR2 receptors which would be predicted to
down-regulate TNF-amediated activation of this transcrip-
tion factor. The NF-kB signaling pathway can activate the
transcription of many genes, including anti-apoptotic genes
such as Bfl-1 (BCL2A1) in neutrophils, but it is activated by
many other receptors such as TLRs, IL-1R. Further analysis
of our previously-published RNA-Seq data (n¼ 4) [36]
(GSE40548) identified significant up regulation of IL-1B
receptor subunit-2 and TLR2 by TNF-a, whilst TLR1 was
significantly down-regulated (FDR< 0.01, Supplementary
Figure S2A). Therefore, it is possible that while TNF-a
signaling may be down-regulated by this mechanism, NF-kB
may still be activated via other inflammatory ligands. In the
experiments described in this report, we have confirmed the
increased expression of Bfl-1 mRNA in response to TNF-a,
but were unable to detect increased expression of the protein
due to lack of an antibody that reliably detects the human
protein. Hence, we could not confirm increased Bfl-1
protein expression following TNF-a treatment, in spite of a
large increase in mRNA levels. As requested by a reviewer,
data for expression levels of a range of metalloproteinases are
shown in Supplementary Figure S2B: expression of these
genes was largely unaffected by TNF-a treatment.
In summary, we have shown that neutrophils adapt to
TNF-a exposure by down-regulating of expression of genes
involved in the death-receptor signaling, and this mecha-
nism is likely to affect the ability of these cells to respond to
this cytokine in inflammatory conditions. Such amechanism
will allow neutrophils to survive and function under TNF-a
-rich inflammatory conditions in vivo. Further work is now
necessary to determine if this transcriptional re-program-
ming occurs in vivo in human diseases driven by TNF-a (e.g.
rheumatoid arthritis).
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SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site
Figure S1. TNF-a delay of neutrophil apoptosis.
Figure S2. Previously published RNA-Seq data deposited in
the NCBI’s Gene Expression Omnibus (GEO) and are
accessible through GEO Series accession number GSE40548
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE40548), were analyzed for relative expression levels
of the listed receptors (A) or metalloproteinases (B).
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